Blog

Russ Cohen

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ — Carisma Therapeutics Inc. CARM (“Carisma” or the “Company”), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET. An audio webcast of the event will ...

Russ Cohen

Options Corner: Microchip Offers A High-Risk Wager Just Ahead Of Earnings

On paper, Microchip Technology Inc. MCHP should rank among the top semiconductor specialists. While it’s not directly tied to artificial intelligence, the Chandler, Arizona-based company plays a powerful supporting role in AI applications. Fundamentally, the company specializes in microcontrollers, analog chips and field-programmable gate arrays (FPGAs) that are essential for embedded AI systems. Encompassing relevancies ...

Russ Cohen

New Strong Buy Stocks for February 7th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Allegiant ALGT: This low-cost passenger airline company which focuses on linking leisure travelers in small and medium sized cities to world-class leisure destinations, has seen the Zacks Consensus Estimate for its current year earnings increasing 10.3% over the last 60 day. ...

Russ Cohen

AMD Q4 Earnings Beat Estimates, Shares Down on Weak Guidance

Advanced Micro Devices AMD reported fourth-quarter 2024 non-GAAP earnings of $1.09 per share, beating the Zacks Consensus Estimate by 1.10%. The figure surged 31.4% year over year.  Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Revenues of $7.658 billion beat the Zacks Consensus Estimate by 1.61% and increased 24.2% year over year, ...

Russ Cohen

Could 2025 Be a Repeat of 2022 for Big Tech?

Investors often love investing in tech stocks because of how much upside there can be in both the short term and long term. Companies involved in next-gen technologies can become incredibly popular, but they can also rise to unsustainable valuations. Back in 2022, tech stocks crashed, and inflated valuations had a lot to do with ...

Russ Cohen

Is Netflix a Buy, Sell, or Hold in 2025?

Netflix (NASDAQ: NFLX) recently reported its fourth quarter 2024 earnings, delighting the market by surpassing 300 million subscribers and $10 billion in quarterly revenue for the first time. With its continued strong performance, the stock has climbed nearly 70% over the past year and now trades near an all-time high. So, let’s dive into the ...

Russ Cohen

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

LOS ANGELES, Feb. 4, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. (“Kyverna” or “the Company”) KYTX for violations of the federal securities laws. Investors who purchased the Company’s securities pursuant and/or traceable to the Company’s offering documents ...